Drug Discovery and Development for Human African Trypanosomiasis

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Neglected Tropical Diseases

• Publication date

  2019-08-02

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1002/9783527808656.ch5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites

  2017cited by this paper
• Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases

  2017cited by this paper
• From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis.

  2017cited by this paper
• Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

  2017cited by this paper
• Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

  2016cited by this paper
• Proteomic Identification of Immunodiagnostic Antigens for Trypanosoma vivax Infections in Cattle and Generation of a Proof-of-Concept Lateral Flow Test Diagnostic Device

  2016cited by this paper
• Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model

  2016cited by this paper
• Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis

  2016cited by this paper
• A novel protein kinase is essential in bloodstream Trypanosoma brucei.

  2016cited by this paper
• Repurposing strategies for tropical disease drug discovery.

  2016cited by this paper
• In Silico Search of Energy Metabolism Inhibitors for Alternative Leishmaniasis Treatments

  2015cited by this paper
• EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.

  2015cited by this paper
• Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk

  2015cited by this paper
• New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource

  2015cited by this paper
• Repurposing Human PDE4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE4 Inhibitor GSK‐256066 as Inhibitors of PDEB1 of Trypanosoma brucei

  2015cited by this paper
• Regulators of Trypanosoma brucei Cell Cycle Progression and Differentiation Identified Using a Kinome-Wide RNAi Screen

  2014cited by this paper
• 45 – Human African Trypanosomiasis

  2014cited by this paper
• Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites

  2014cited by this paper
• Sleeping Sickness Epidemics and Colonial Responses in East and Central Africa, 1900–1940

  2014cited by this paper
• Establishment of a Structure–Activity Relationship of 1H-Imidazo[4,5-c]quinoline-Based Kinase Inhibitor NVP-BEZ235 as a Lead for African Sleeping Sickness

  2014cited by this paper
• Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis.

  2014cited by this paper
• A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis

  2013cited by this paper
• Drug discovery and human African trypanosomiasis: a disease less neglected?

  2013cited by this paper
• Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines

  2013cited by this paper
• The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

  2013cited by this paper
• Rapid diagnostic tests for neurological infections in central Africa.

  2013cited by this paper
• Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds

  2013cited by this paper
• Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter

  2013cited by this paper
• Efficient Iron Uptake via a Reductive Mechanism in Procyclic Trypanosoma brucei

  2013cited by this paper
• Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.

  2013cited by this paper
• Chemical Proteomic Analysis Reveals the Drugability of the Kinome of Trypanosoma brucei

  2012cited by this paper
• Drug Repurposing: Far Beyond New Targets for Old Drugs

  2012cited by this paper
• Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei

  2012cited by this paper
• Antiparasitic agents: new drugs on the horizon.

  2012cited by this paper
• Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

  2011cited by this paper
• Histone deacetylases as regulators of inflammation and immunity.

  2011cited by this paper
• Drug discovery and development for neglected diseases: the DNDi model

  2011cited by this paper
• Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping Sickness

  2011cited by this paper
• SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis

  2011cited by this paper
• High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

  2011cited by this paper
• A Structure–Activity Relationship Study of the Antimalarial and Antileishmanial Activities of Nonpeptide Macrocyclic Histone Deacetylase Inhibitors

  2010cited by this paper
• Human African trypanosomiasis

  2010cited by this paper
• A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes

  2010cited by this paper
• A Target-Based High Throughput Screen Yields Trypanosoma brucei Hexokinase Small Molecule Inhibitors with Antiparasitic Activity

  2010cited by this paper
• Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

  2010cited by this paper
• Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis

  2010cited by this paper
• A new format of the CATT test for the detection of Human African Trypanosomiasis, designed for use in peripheral health facilities

  2010cited by this paper
• Rational design of indoleamine 2,3-dioxygenase inhibitors.

  2010cited by this paper
• Human African Trypanosomiasis in Areas without Surveillance

  2010cited by this paper
• Drug Resistance in African Trypanosomiasis

  2009cited by this paper
• High-throughput and in silico screenings in drug discovery

  2009cited by this paper
• Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.

  2009cited by this paper
• Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity

  2009cited by this paper
• Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis

  2009cited by this paper
• Kinetoplastid papain-like cysteine peptidases.

  2009cited by this paper
• Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey

  2009cited by this paper
• The history of African trypanosomiasis

  2008cited by this paper
• FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

  2008cited by this paper
• Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease

  2007cited by this paper
• In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.

  2006cited by this paper
• Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Uganda

  2006cited by this paper
• Apolipoprotein L-I Promotes Trypanosome Lysis by Forming Pores in Lysosomal Membranes

  2005cited by this paper
• Options for Field Diagnosis of Human African Trypanosomiasis

  2005cited by this paper
• The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronicT. brucei infections in mice

  2004cited by this paper
• Bloodstream Form-specific Up-regulation of Silent VSG Expression Sites and Procyclin in Trypanosoma brucei after Inhibition of DNA Synthesis or DNA Damage*

  2004cited by this paper
• Fosmidomycin for the treatment of malaria

  2003cited by this paper
• Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with pentamidine.

  2003cited by this paper
• Nitroheterocyclic drugs with broad spectrum activity

  2003cited by this paper
• The origins of a new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda.

  2001cited by this paper
• Trypanosomosis agglutination card test for Trypanosoma brucei rhodesiense sleeping sickness.

  1999cited by this paper
• The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis.

  1996cited by this paper
• Recent research on the biological activity of suramin.

  1993cited by this paper
• Persistence of antibodies to Trypanosoma brucei gambiense after treatment of human trypanosomiasis in Uganda.

  1992cited by this paper
• The pathogenesis of sleeping sickness.

  1980cited by this paper
• A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis.

  1978cited by this paper
• Sleeping sickness in Europeans: a review of 109 cases.

  1966cited by this paper

• Extracts of the cyanobacteria Microcystis flos-aquae contain potent anti-Trypanosoma compounds

  2024cites this paper
• An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases

  2021cites this paper
• TrypInDB: A searchable online resource of small molecule inhibitors against Trypanosoma sp.

  2020cites this paper